The Increasingly Stormy Waters of US Market Access
The US reimbursement landscape has been shifting rapidly over the last few years. We invited 31 MCO leaders to discuss the key trends.
top of page
Vocal.
Search
Ulrich Neumann, MBA MSc MA
- Oct 14, 2020
- 6 min
Getting Asset Evaluation Right
Evaluating drug candidates for M&A is of the essential parts of R&D innovation. This article proposes an interdisciplinary approach.
Ulrich Neumann, MBA MSc MA
- Aug 20, 2020
- 9 min
Paying for Cell & Gene Therapy in the US: Is the Future Already Here?
Multiple novel payment models for CGT are currently deployed but an open and collaborative innovation approach among stakeholders is needed.
Ulrich Neumann, MBA MSc MA
- Apr 10, 2020
- 7 min
New approaches to pharma sales: Success is marrying data analytics with the art of 1-1 engagement
In a world post-COVID, customer engagement matters more than ever before. Reflections on rethinking engagement in the field post pandemic.
Ulrich Neumann, MBA MSc MA
- Feb 29, 2020
- 13 min
Netflix’s revenue model as a blueprint for pharmaceutical pricing?
An analysis of the economic and behavioral forces that led to the first adoption of subscription-based pricing for pharmaceuticals.
Directly blog
bottom of page